ATOSSA THERAPEUTICS, INC.
ATOS · XNASCIK 1488039fmd_1RVX4BFCWVZQ5XFGGQTP56ZN23Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 62 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 1 | 2 | 4 | 7 | 7 | 9 | 15 | 17 | 14 | 21 |
| Total operating expenses | 8 | 8 | 11 | 17 | 15 | 21 | 28 | 31 | 28 | 37 |
| Operating income | (8) | (8) | (11) | (17) | (15) | (21) | (28) | (31) | (28) | (37) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | 0 | 1 | 4 | 4 | 2 |
| Other non-operating income (expense) | 2 | 0 | 0 | 0 | 0 | (0) | (0) | (0) | (0) | (0) |
| Income before taxes | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| Net income | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| Net income to common shareholders | (6) | (11) | (23) | (17) | (22) | (21) | – | – | – | – |